Prevention and treatment of urothelial premalignant and malignant lesions

H. Wijkström, S. M. Cohen, R. A. Gardiner, T. Kakizoe, Mark P. Schoenberg, G. Steineck, K. Tobisu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bladder cancer is believed to develop through reversible premalignant stages followed by irreversible steps, and ending in invasive cancer giving rise to distant metastases. Because of the variation in the clinical course it has also been suggested that different forms of cancer develop along different molecular pathways leading to tumor presentations of various malignant potential. Today we treat and prognosticate bladder cancer on the basis of clinical and histologic findings that are insufficient to assess all the biologic potential of these tumors. Understanding the pathogenesis of bladder cancer might lead to a more precise identification of particular tumors with regard to clinical aggressiveness, resulting in individualized strategies for treatment and prophylaxis. Bladder cancer is seldom diagnosed in its preclinical stage, it is instead detected at cystoscopy and virtually never recognized as an incidental finding on autopsy. Therefore its "natural history" largely reflects that of "treated" disease. The true incidence of premalignant and malignant epithelial changes is not known. Incidences of hyperplasia and dysplasia of ≈10% and ≈5%, respectively and only occasional findings of cancer itself were reported in two autopsy series. Urothelial dysplasia is generally believed to be premalignant and a putative precursor of invasive cancer but unfortunately there has been a lack of standardization in terms of terminology and diagnosis. There is also a need for an agreed definition of the boundary between premalignancy, i.e. urothelial changes that have some but not all the features of carcinoma in situ, and malignancy, especially when considering potentially harmful treatments to prevent this transition. Most new diagnostic tools available and being tested today compare new detection techniques with traditional methods such as cytology or conventional histology of malignant rather than premalignant changes. There is probably also a short preclinical latency, as implied by the incidental findings of bladder cancer at autopsy, which makes it necessary to define how and when to promote early detection and treatment. Future studies therefore have to concentrate on methods for early detection of disease as well as characterization of host susceptibility, evaluation of exposure to carcinogens and potential effects of preventive measures. It is also likely that the improved tools of molecular prognostication will allow us to design trials more precisely in order to tailor therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)116-135
Number of pages20
JournalScandinavian Journal of Urology and Nephrology, Supplement
Volume34
Issue number205
StatePublished - 2000
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Autopsy
Incidental Findings
Cystoscopy
Incidence
Carcinoma in Situ
Therapeutics
Natural History
Terminology
Carcinogens
Hyperplasia
Cell Biology
Early Diagnosis
Histology
Neoplasm Metastasis

Keywords

  • Malignant lesions
  • Premalignant lesions
  • Prevention
  • Treatment
  • Urothelium

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Wijkström, H., Cohen, S. M., Gardiner, R. A., Kakizoe, T., Schoenberg, M. P., Steineck, G., & Tobisu, K. (2000). Prevention and treatment of urothelial premalignant and malignant lesions. Scandinavian Journal of Urology and Nephrology, Supplement, 34(205), 116-135.

Prevention and treatment of urothelial premalignant and malignant lesions. / Wijkström, H.; Cohen, S. M.; Gardiner, R. A.; Kakizoe, T.; Schoenberg, Mark P.; Steineck, G.; Tobisu, K.

In: Scandinavian Journal of Urology and Nephrology, Supplement, Vol. 34, No. 205, 2000, p. 116-135.

Research output: Contribution to journalArticle

Wijkström, H, Cohen, SM, Gardiner, RA, Kakizoe, T, Schoenberg, MP, Steineck, G & Tobisu, K 2000, 'Prevention and treatment of urothelial premalignant and malignant lesions', Scandinavian Journal of Urology and Nephrology, Supplement, vol. 34, no. 205, pp. 116-135.
Wijkström, H. ; Cohen, S. M. ; Gardiner, R. A. ; Kakizoe, T. ; Schoenberg, Mark P. ; Steineck, G. ; Tobisu, K. / Prevention and treatment of urothelial premalignant and malignant lesions. In: Scandinavian Journal of Urology and Nephrology, Supplement. 2000 ; Vol. 34, No. 205. pp. 116-135.
@article{4031a5415381467cb7b310a50b3339bc,
title = "Prevention and treatment of urothelial premalignant and malignant lesions",
abstract = "Bladder cancer is believed to develop through reversible premalignant stages followed by irreversible steps, and ending in invasive cancer giving rise to distant metastases. Because of the variation in the clinical course it has also been suggested that different forms of cancer develop along different molecular pathways leading to tumor presentations of various malignant potential. Today we treat and prognosticate bladder cancer on the basis of clinical and histologic findings that are insufficient to assess all the biologic potential of these tumors. Understanding the pathogenesis of bladder cancer might lead to a more precise identification of particular tumors with regard to clinical aggressiveness, resulting in individualized strategies for treatment and prophylaxis. Bladder cancer is seldom diagnosed in its preclinical stage, it is instead detected at cystoscopy and virtually never recognized as an incidental finding on autopsy. Therefore its {"}natural history{"} largely reflects that of {"}treated{"} disease. The true incidence of premalignant and malignant epithelial changes is not known. Incidences of hyperplasia and dysplasia of ≈10{\%} and ≈5{\%}, respectively and only occasional findings of cancer itself were reported in two autopsy series. Urothelial dysplasia is generally believed to be premalignant and a putative precursor of invasive cancer but unfortunately there has been a lack of standardization in terms of terminology and diagnosis. There is also a need for an agreed definition of the boundary between premalignancy, i.e. urothelial changes that have some but not all the features of carcinoma in situ, and malignancy, especially when considering potentially harmful treatments to prevent this transition. Most new diagnostic tools available and being tested today compare new detection techniques with traditional methods such as cytology or conventional histology of malignant rather than premalignant changes. There is probably also a short preclinical latency, as implied by the incidental findings of bladder cancer at autopsy, which makes it necessary to define how and when to promote early detection and treatment. Future studies therefore have to concentrate on methods for early detection of disease as well as characterization of host susceptibility, evaluation of exposure to carcinogens and potential effects of preventive measures. It is also likely that the improved tools of molecular prognostication will allow us to design trials more precisely in order to tailor therapeutic strategies.",
keywords = "Malignant lesions, Premalignant lesions, Prevention, Treatment, Urothelium",
author = "H. Wijkstr{\"o}m and Cohen, {S. M.} and Gardiner, {R. A.} and T. Kakizoe and Schoenberg, {Mark P.} and G. Steineck and K. Tobisu",
year = "2000",
language = "English (US)",
volume = "34",
pages = "116--135",
journal = "Scandinavian Journal of Urology and Nephrology, Supplement",
issn = "0300-8886",
publisher = "Taylor and Francis Ltd.",
number = "205",

}

TY - JOUR

T1 - Prevention and treatment of urothelial premalignant and malignant lesions

AU - Wijkström, H.

AU - Cohen, S. M.

AU - Gardiner, R. A.

AU - Kakizoe, T.

AU - Schoenberg, Mark P.

AU - Steineck, G.

AU - Tobisu, K.

PY - 2000

Y1 - 2000

N2 - Bladder cancer is believed to develop through reversible premalignant stages followed by irreversible steps, and ending in invasive cancer giving rise to distant metastases. Because of the variation in the clinical course it has also been suggested that different forms of cancer develop along different molecular pathways leading to tumor presentations of various malignant potential. Today we treat and prognosticate bladder cancer on the basis of clinical and histologic findings that are insufficient to assess all the biologic potential of these tumors. Understanding the pathogenesis of bladder cancer might lead to a more precise identification of particular tumors with regard to clinical aggressiveness, resulting in individualized strategies for treatment and prophylaxis. Bladder cancer is seldom diagnosed in its preclinical stage, it is instead detected at cystoscopy and virtually never recognized as an incidental finding on autopsy. Therefore its "natural history" largely reflects that of "treated" disease. The true incidence of premalignant and malignant epithelial changes is not known. Incidences of hyperplasia and dysplasia of ≈10% and ≈5%, respectively and only occasional findings of cancer itself were reported in two autopsy series. Urothelial dysplasia is generally believed to be premalignant and a putative precursor of invasive cancer but unfortunately there has been a lack of standardization in terms of terminology and diagnosis. There is also a need for an agreed definition of the boundary between premalignancy, i.e. urothelial changes that have some but not all the features of carcinoma in situ, and malignancy, especially when considering potentially harmful treatments to prevent this transition. Most new diagnostic tools available and being tested today compare new detection techniques with traditional methods such as cytology or conventional histology of malignant rather than premalignant changes. There is probably also a short preclinical latency, as implied by the incidental findings of bladder cancer at autopsy, which makes it necessary to define how and when to promote early detection and treatment. Future studies therefore have to concentrate on methods for early detection of disease as well as characterization of host susceptibility, evaluation of exposure to carcinogens and potential effects of preventive measures. It is also likely that the improved tools of molecular prognostication will allow us to design trials more precisely in order to tailor therapeutic strategies.

AB - Bladder cancer is believed to develop through reversible premalignant stages followed by irreversible steps, and ending in invasive cancer giving rise to distant metastases. Because of the variation in the clinical course it has also been suggested that different forms of cancer develop along different molecular pathways leading to tumor presentations of various malignant potential. Today we treat and prognosticate bladder cancer on the basis of clinical and histologic findings that are insufficient to assess all the biologic potential of these tumors. Understanding the pathogenesis of bladder cancer might lead to a more precise identification of particular tumors with regard to clinical aggressiveness, resulting in individualized strategies for treatment and prophylaxis. Bladder cancer is seldom diagnosed in its preclinical stage, it is instead detected at cystoscopy and virtually never recognized as an incidental finding on autopsy. Therefore its "natural history" largely reflects that of "treated" disease. The true incidence of premalignant and malignant epithelial changes is not known. Incidences of hyperplasia and dysplasia of ≈10% and ≈5%, respectively and only occasional findings of cancer itself were reported in two autopsy series. Urothelial dysplasia is generally believed to be premalignant and a putative precursor of invasive cancer but unfortunately there has been a lack of standardization in terms of terminology and diagnosis. There is also a need for an agreed definition of the boundary between premalignancy, i.e. urothelial changes that have some but not all the features of carcinoma in situ, and malignancy, especially when considering potentially harmful treatments to prevent this transition. Most new diagnostic tools available and being tested today compare new detection techniques with traditional methods such as cytology or conventional histology of malignant rather than premalignant changes. There is probably also a short preclinical latency, as implied by the incidental findings of bladder cancer at autopsy, which makes it necessary to define how and when to promote early detection and treatment. Future studies therefore have to concentrate on methods for early detection of disease as well as characterization of host susceptibility, evaluation of exposure to carcinogens and potential effects of preventive measures. It is also likely that the improved tools of molecular prognostication will allow us to design trials more precisely in order to tailor therapeutic strategies.

KW - Malignant lesions

KW - Premalignant lesions

KW - Prevention

KW - Treatment

KW - Urothelium

UR - http://www.scopus.com/inward/record.url?scp=0034353129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034353129&partnerID=8YFLogxK

M3 - Article

C2 - 11144892

AN - SCOPUS:0034353129

VL - 34

SP - 116

EP - 135

JO - Scandinavian Journal of Urology and Nephrology, Supplement

JF - Scandinavian Journal of Urology and Nephrology, Supplement

SN - 0300-8886

IS - 205

ER -